The incidence and course of pulmonary hypertension in systemic lupus erythematosus patients. Three years follow up outcome;Výskyt a průběh plicní hypertenze u systémového lupus erythematodes. Výsledky tříletého sledování

Ceska Revmatologie

Volumn 11, Issue 3, 2003, Pages 117-127

  Tegzova D ^e   Kamenik L ^a   Musilova L ^e   Stolfa J ^e   Forejtova S ^e   Soukup, T ^b   Dorazilova A ^c   Al Hiti, H ^d   Dostal C ^e  

^a Nemocnice Milosrdnych Sester   (Czech Republic)

^b II Interni Klinika   (Czech Republic)

^c Anatomicky Ustav 1 LF UK   (Czech Republic)

^d INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^e INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

Author keywords

Antiphospholipid antibodies; Heart failure; Organ manifestation; Pulmonary embolism; Pulmonary hypertension; Systemic lupus erythematosus; Therapy; Vasculopathy

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DNA ANTIBODY; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; PHOSPHOLIPID ANTIBODY; PREDNISONE; VASODILATOR AGENT;

ADULT; ANTIBODY SCREENING; ARTERY INTIMA PROLIFERATION; ARTICLE; AUTOPSY; CAUSE OF DEATH; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DYSPNEA; ECHOCARDIOGRAPHY; FATALITY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEART CATHETERIZATION; HEART FAILURE; HEMANGIOMATOSIS; HUMAN; INCIDENCE; LABORATORY TEST; LUNG ARTERY; LUNG DISEASE; LUNG EMBOLISM; LUNG INJURY; LUNG INTERSTITIUM; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MICROTHROMBUS; OUTCOMES RESEARCH; PSYCHOPATHY; PULMONARY HYPERTENSION; RADIOGRAPHY; RAYNAUD PHENOMENON; RISK FACTOR; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE; VASCULITIS; VASODILATATION;

EID: 0141927094     PISSN: 12107905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Orens BJ, Metinez FJ, Lynch FJ, Lynch JP. Pleuro-pulmonary manifestations of systemic lupus erythematosus. From: Rheumatic Disease Clinics of North America. 1994; Vol, 20, No. 1: 159-93.
2. Asherson RA, Mackworth-Young CG, Boey ML, et al. Pulmonary hypertension in systemic lupus erythematosus. B M J 1983; 287: 1024-5.
3. Alarcon-Segovia D. Alarcon DG. Pleuro-pulmonary manifestations of systemic lupus erythematosus. Chest 1961; 39:7-17.
4. Rich S. Executive Summary from the World Symposium on primary pulmonary hypertension 1998. http://www.who.int/ncd/cvd/pph.html.
5. Gaine S, Rublin L. Primary pulmonary hypertension. Lancet, 1998; 352: 9124.
6. Gaine SP: Pulmonary hypertension. JAMA 2000; 284: 3160-8.
7. Wagenvoort C, Wagenvoort N. Pathology of pulmonary hypertension. New Yourk, NY: John Wiley and Sons, 1997.
8. Groen H, TerBorg EJ, Postma DS, et al. Pulmonary function in systemic lupus erythematosus is related to distinct clinical, serologic and nailfold capilary patterns. Am J Med 1992; 93: 619-27.
9. Yokoi T, Tomita Y, Fukaya M, et al. Pulmonary hypertension associated with systemic lupus erythematosus: predominantly thrombotic arteriopathy accompanied by plexiform lesions.Arch Pathol Lab Med 1998; 122(5): 467-70.
10. Tuder RM, Groves B, Badesch DB. Exuberant endothelial cell geowth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275-85.
11. Rich S, Kaufmann E, Evy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med, 1992; 327: 76-81.
12. Bailey CL,Channick RN, Rubin LJ. A new area in the treatment of primary pulmonary hypertension. Heart 2001; 85: 251-2.
13. Humbert M, Sanchez O, Fartouk M, et al. Short-term and long-term epoprostenol therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999; 13: 1351-6.
14. Robbins IM, Gaine SP, Shilz R, et al. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000; 117: 14-18.
15. Badesch DB,Tason VF,Mc Goon MD, et al. Continos intravenous epoprostenol for pulmonary hypertension due to scleroderma sectrum of disease. Ann Intern Med 2000; 6: 425-.
16. McLaughin VV. Medical managment of primary pulmonary hypertension. Expert Opin Pharmacother 2002; 3: 159-65.
17. Hoeper M, Galie N, Simonneau G, Rubin LJ. Pulmonary perspective: New treatments for pulmonary arterial hypertension. Am J Resp Crit Care Med 2002; 165: 1209-16.
18. Hall RJ et al. Recomendations on the management of pulmonary hypertension in clinic practice. Heart 2001; Suppl, 86: 1-11.
19. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of aoutpatients with pulmonary hypertenson. J Am Coll cardiol 1999; 34: 1188-92.
20. Hoeper MM, Schwarze, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Eng J Med 2000; 342: 1866.
21. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J med 2002; 347: 322-9.
22. Simonneau G, Barst RJ, Galie N, et al. Continoius subcutaneous infusion of treprostinol, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double blind randomized controlled tria. Am J Respir Cit Care med 2002; 165: 800-4.
23. Luscher TF, Barton M. Endothelin receptor antagonists: therapeutic considerations for a ovel class of cardiovascular drugs. Circulation 2000; 102: 2434-40.
24. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary artery hypertension: A randomised placebo-controlled study. Lancet 2001; 358: 1119-23.
25. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension: a randomised, placebo controlled, mltcenter study. N Engl J Med 2002; 346: 896-903.
26. Moncada S, Higgs A. The arginine-nitrid oxide pathway. N Engl J Med 1993; 329: 2002-12.
27. Nagaya N, Uematsu M, Oya H, et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med 2001; 163: 887-91.
28. Mehta S, Steward DJ, Langleben D. Short-term pulmonary vasodilatation with L-argiine in pulmonary hypertension. Circulatio 1995; 92: 1539-45.
29. Kleinsasser A, Loeckinger A, Hoermann C, et al. Sildenafil modulates hemodynamics abd pulmonary gas exchange. Am J Respir Crit Care Med 2001; 163: 339-43.
30. Cowan KN, Helbut A, Humpl T, et al. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000; 6: 698-702.
31. Nootens M, Schrader B, Kaufmann, et al. Comparative effects of adenosine and prostacyclin in primary pulmonary hypertrension. Chest 1995; 107: 54-57.
32. Gaine SP, Rubin LJ. Medial and surgical treatment options for pulmonary hypertension. Am J Med Sci 1988; 315: 179.
33. Sandoval, Gaspar J, Pulido T, et al. Graded balloon dilaton arterial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients non-responsive to vasodlator treatment. J Am Coll Cardiol 1988; 32: 297.